Drugs in Dev. Podiatry
Phase I/ Phase II
Lead Product(s) : R327
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Pharmaceuticals Expands Phase I/II Trial of RECCE® 327 for Diabetic Foot Infections
Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : R327
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recce Reports Positive Phase I/II Results of RECCE® 327 for Diabetic Infections
Details : RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 23, 2024
Lead Product(s) : R327
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for Diabetic Foot Infections.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 24, 2023
Lead Product(s) : R327
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R327
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Murdoch Children’s Research Institute
Deal Size : Undisclosed
Deal Type : Agreement
Details : The company’s work with Murdoch Children's has already played a pivotal role in the delivery of results surrounding ongoing pre-clinical programs, generating R327 (RECCE 327) data demonstrating strong bactericidal activity against a range of deadly pat...
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Undisclosed
December 19, 2022
Lead Product(s) : R327
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Murdoch Children’s Research Institute
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : R327
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RECCE® 327 (R327) is one of the first new classes of antibiotics in over 30 years with a universal mechanism of action that allow its compounds to continuously kill bacteria and multi-drug resistant superbugs.
Product Name : RECCE 327
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : R327
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the license and collaboration agreement, Xbiome acquires exclusive development and commercial rights for all human use to Aurealis clinical stage DFU drug candidate AUP-16 in Mainland China, Hong Kong, Macao, and Taiwan.
Product Name : AUP-16
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 28, 2022
Lead Product(s) : AUP-16
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Xbiome
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
